Hassan Abolhassani is an expert in Immunology at Karolinska Institute (Sweden). As of October 2026, ScienceLeadR ranks Hassan Abolhassani in the top 1% of experts worldwide for Immunologic Deficiency Syndromes, and in the top 1% of experts in Sweden for Telangiectasis and DNA Repair-Deficiency Disorders. Hassan Abolhassani has authored 454 publications, the most recent in 2026, and is an investigator in 1 clinical trial. SLR score: 1,056 (community average: 125). How the SLR is computed.

LeadR Profile

Hassan Abolhassani Karolinska Institute Sweden
1 056 ScienceLeadR Reputation 1056
Network Map

Immunology

Subspecialties: Public Health - Infectiology - Genetics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2011 - 2026

Source: PubMed

Tehran University of Medical Sciences

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 454

Citations

Citations: 64 287 1st author: 39 Last author: 26 Unique author: 1


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Correction to: Cancer Trends in Inborn Errors of Immunity: A Systematic Review and Meta‑Analysis.
PMID 42825962 — neoplasms, immunity
J Clin Immunol20260
Human-inherited RORγT deficiency encompasses genetic heterogeneity, T cell deficiency, and clinical homogeneity.
PMID 42695969 — cells, mycobacterium, genetic heterogeneity, t-lymphocytes
J Exp Med20260
Neurological effects of encapsulated dexamethasone sodium phosphate in children aged 6-9 years with ataxia telangiectasia (NEAT): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
PMID 42600624 — safety, dexamethasone, telangiectasis, signs and symptoms, aged, drug-related side effects and adverse reactions, ataxia telangiectasia, ataxia, therapeutics, pediatrics, child
Lancet Child Adolesc Health20260
Precision Oncology in Thymic Epithelial Tumors: Therapeutic Horizons and Implementation Barriers.
PMID 42589271 — cells, neoplasms, biomarkers, therapeutics
Int J Mol Sci20260
Human inherited RORγT deficiency encompasses genetic heterogeneity, T cell deficiency, and clinical homogeneity.
PMID 42539146 — cells, mycobacterium, genetic heterogeneity, t-lymphocytes
medRxiv20260

Clinical Studies 1

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 1

By status:

Completed 1

By type:

Interventional 1

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 0
multicentricup10 1

Main Topics

Cohort/Consortium Investigators 8

LeadR Networks

Main global connection map